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Leishmaniasis is a protozoan disease whose diverse
clinical manifestations are dependent both on the
infecting species of Leishmania and the immune
response of the host. Transmission of the disease
occurs by the bite of a sand ¯y infected with
Leishmania parasites. Infection may be restricted to
the skin in cutaneous leishmaniasis, limited to the
mucous membranes in mucosal leishmaniasis, or
spread internally in visceral leishmaniasis or kala
azar. The overall prevalence of leishmaniasis is 12
million cases worldwide, and the global yearly
incidence of all clinical forms approaches 2 million
new cases (World Health Organization WHO/
LEISH/200.42, Leishmania/HIV Co-Infection in
Southwestern Europe 1990±98: Retrospective Analysis of
965 Cases, 2000). In the last two decades, leishmania-
sis, especially visceral leishmaniasis, has been recog-
nized as an opportunistic disease in the
immunocompromised, particularly in patients
infected with human immunode®ciency virus.
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HISTORY
The increases in travel and the number of immunocompromised
individuals allows leishmaniasis to be considered an ``emerging
disease''. The purpose of this paper is to highlight selected clinical,
histopathologic, and immunologic features of leishmaniasis as well
as therapies and vector biology.
The cutaneous af¯ictions of leishmaniasis have been known since
antiquity (Peters, 1988). Descriptions of the cutaneous disease in
the Old World are found from the ®rst century AD. New World
pottery from Peru and Ecuador dating from AD 400±900 illustrates
faces af¯icted with a process consistent with leishmaniasis (Lainson
et al, 1987). The ®rst description in English of a lesion resembling
leishmaniasis was made in 1756 by Russell, who described the
``Aleppo evil'' from Syria. In 1885, Cunningham observed
organisms in macrophages from lesions of ``Delhi boil'' in India.
A Russian army physician named Borovsky noted the protozoal
nature of the organism in 1898 in biopsy specimens from skin
lesions. In 1903 Leishman published his identi®cation of the
parasite in the spleen of an English private who had died of
Dumdum fever in Dum-Dum, India in 1900. A few months later
Donovan described identical organisms in a splenic puncture
specimen from a living child. The distinctive histologic feature of
this 2±5 mm parasite was the presence of both a nucleus and a
smaller rod-shaped structure consisting of mitochondrial DNA
called the kinetoplast. Ross named the parasite ``Leishmania
donovani'' later the same year. Other names of leishmaniasis
include Oriental sore, Aleppo evil, Delhi boil, Baghdad sore, Rose
of Jericho, Chiclero's ulcer, uta, espundia (mucous form), forest
yaws, Dumdum fever (visceral form), kala-azar, and black fever.
CLINICAL FEATURES
Localized cutaneous leishmaniasis (LCL) Leishmaniasis in
its various forms is present on all continents except Australia and
Antarctica (Lerner and Von Lichtenburg, 1991). LCL is widespread
throughout the Old World and is primarily caused by the organisms
Leishmania tropica and Leishmania major. New world LCL is endemic
in Central and South America. Two independent species or
``complexes'' of parasites are responsible for New World LCL:
Leishmania braziliensis and Leishmania mexicana.
LCL usually affects unclothed parts of the body easily bitten by
the sand ¯y vector, including the face, neck, and arms. New World
leishmaniasis commonly presents with a solitary primary lesion,
whereas multiple primary lesions are often found in Old World
disease. After an average incubation period of 1 wk to 3 mo, a red
papule appears that enlarges to a plaque or nodule. The lesion often
develops into an ulcer, which is well circumscribed with a
violaceous border. The ulcer base is granulomatous and crusted,
and the margins are hypertrophic but without extensive under-
mining (Fig 1). Painless, rubbery subcutaneous nodules or cords
rarely develop around the ulcer due to local lymphangitic spread of
the organism. Draining lymph nodes may be enlarged and reveal
parasites on biopsy (Al-Gindan and Kubba, 1989). Occasionally,
in¯ammatory satellite papules and subcutaneous induration may
develop around the primary lesion representing a reaction to local
dissemination of the parasite or its antigenic products (Kubba et al,
1987, 1988). Itching and pain are mild, if present. The wound may
become superinfected, leading to misdiagnosis. Between 1 and
36 mo, depending upon both the patient and the infecting
organism, the ulcer spontaneously regresses leaving a scar with
hypo- or hyper-pigmentation. Immunity is considered complete
but one study in a Saudi Arabian population found subsequent re-
infection in up to 10% of individuals (Killick-Kendrick et al, 1985).
Diffuse cutaneous leishmaniasis (DCL) DCL is an anergic
variant of LCL in which lesions are disseminated, resembling
lepromatous leprosy. Infection may be caused by Leishmania
aethiopica or, in Central and South America, Leishmania
amazonensis. The disease usually begins with an initial primary
lesion and then disseminates to involve other areas of the skin. The
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lesions are nonulcerative nodules full of parasites, which are often
scattered over the limbs, buttocks, and face. Unlike lepromatous
leprosy, there is no nerve involvement. The disease does not invade
internal organs, but responds only partially to treatment and often
relapses, becoming chronic.
Post kala-azar dermal leishmaniasis (PKDL) PKDL is
primarily caused by Leishmania donovani and is endemic in East
Africa and India. In Africa, PKDL occurs in up to 50% of patients
recovering from visceral leishmaniasis (Zijlstra et al, 1994) The rash
generally consists of discrete skin-colored or hyperpigmented
papules on the cheeks, chin, ears, and extensor aspects of
forearms. Most lesions heal spontaneously over a few months.
In contrast to African PKDL, Indian PKDL occurs in 20% of
patients approximately 1±2 y after recovery (Rees and Kager,
1987). Small hypopigmented macules are usually the ®rst mani-
festation of PKDL and these enlarge to form large irregular patches.
Lesions are often bilateral and symmetrical. The pigmentary loss is
never complete, and there is no pigment change in the hair
overlying the lesions. Erythematous macules develop next, often on
the face in a malar distribution, but may also develop in other areas,
especially in the hypopigmented patches. Finally, soft, painless,
nonulcerative, yellowish-pink nodules replace the hypopigmented
and erythematous macules, and sometimes develop de novo.
Nodules most commonly affect the face, earlobes, trunk, and
genitalia, and less frequently occur on the hands and feet. Cases of
PKDL are dif®cult to treat, requiring longer duration of systemic
medication. Hypopigmented areas almost never completely repig-
ment.
Mucocutaneous leishmaniasis (MCL) MCL is most
commonly reported in the New World (Abdalla et al, 1975;
Marsden, 1986). Leishmania braziliensis is the most common
etiologic agent although there have been several reports of
mucocutaneous disease due to Leishmania panamensis, increasing
the risk that travelers to Central America could potentially develop
MCL (Melby et al, 1992). Fifty per cent of patients develop
mucocutaneous lesions within 2 y of the initial cutaneous lesions,
and 90% within 10 y (Fig 2). Approximately one-third of patients
have no prior history of skin lesions. MCL typically affects a small
percentage (approximately 3%) of individuals previously infected
with L. braziliensis subspecies, although a prevalence as high as 34%
in endemic areas has been reported (Kerdel-Vegas, 1982). Mucous
membrane involvement probably develops due to hematogenous
or lymphatic dissemination, or occasionally from direct extension
of nearby skin lesions. The disease often begins in the nasal septum
which becomes in¯amed and in®ltrated and subsequently
perforates. Malnutrition and pneumonia are the leading causes of
death in patients with MCL.
Visceral leishmaniasis (VL) Kala-azar or VL is a systemic
disease caused by the dissemination of Leishmania donovani or
Leishmania infantum. The advent of human immunode®ciency virus
(HIV) has increased the population of individuals af¯icted by VL
and is discussed later in this report. Characteristic signs and
symptoms include fever, splenomegaly, lymphadenopathy,
emaciation, pancytopenia, and hyperglobulinemia. The primary
lesion of VL is rarely seen but consists of a small erythematous
papule sometimes referred to as a ``leishmanioma''. During the
active period of VL a diffuse blackening of the skin appears that is
the origin of the name ``kala-azar'', meaning ``black fever''. After
an incubation period of 2±4 mo, VL runs an insidious chronic
course until treated. Although the disease is associated with an
increase in serum IgG and IgM, there is a depression of cell-
mediated immunity that predisposes the host to multiple secondary
infections (Haldar et al, 1983). Treatment is usually successful in the
absence of immunode®ciency but relapses have been reported
(Berman, 1997). One source of such relapses is the observation that
parasites have been demonstrated to persist up to 11 y following
clinical cure (Schubach et al, 1998).
Viscerotropic leishmaniasis Leishmania tropica, which had
been thought to cause cutaneous disease exclusively, was found
to be the causative organism in several cases of VL reported in
soldiers of Operation Desert Storm returning from Saudi Arabia
(Magill et al, 1993). The clinical presentations were distinct from
visceral leishmaniasis caused by L. donovani and incuded high fever,
malaise, intermittent diarrhea, and abdominal pain.
PATHOLOGY
Histopathologic studies reveal epidermal and/or dermal changes,
depending on the type and stage of the disease (Kurban et al, 1966).
The diagnostic histopathologic changes of leishmaniasis, however,
are usually present in the dermis. There is a predominantly
mononuclear dermal in®ltrate consisting primarily of lymphocytes
and histiocytes. The histiocytes may be ®lled with Leishman-
Figure 2. Mucocutaneous leishmaniasis. Young man with healed
prior lesions of cutaneous leishmaniasis on the arms caused by
L. braziliensis, now presenting with new lesions of the nasal mucosa.
Figure 1. Localized cutaneous leishmaniasis. Ulcer of the lower
extremity caused by L. major.
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Donovan (L-D) bodies, which are 2±4 mm oval encapsulated
protozoa with a large peripheral nucleus and a smaller rod-shaped
kinetoplast of mitochondrial DNA. L-D bodies are numerous in
early lesions of LCL and PKDL, very abundant in DCL, but scanty
in MCL, VL, and leishmaniasis recidivans, an unusual form of the
disease not discussed here in detail. The lymphohistiocytic in®ltrate
is arranged diffusely in cutaneous forms of leishmaniasis, except in
PKDL and leishmaniasis recidivans where well-organized granulo-
mas are seen. Langerhan's epithelial giant cells may be present
within the granulomas. Plasma cells may also be abundant,
especially in MCL. The in®ltrate extends from the upper to
lower dermis, sometimes around a central necrotic zone where
®brinoid degeneration of vessels may be present.
Immunophenotypic analysis of cell subsets in LCL lesions reveals
an abundance of T cells with an activated phenotype, expressing
interleukin-2 (CD25+), transferrin receptors (CD71+), or major
histocompatibility complex class II molecules on their surface
(Esterre et al, 1992). Equal numbers of CD4+ and CD8+
lyphocytes are present in LCL lesions. In addition, whereas the
majority of T cells in control skin biopsies bear the TCR ab
complex, 20%±30% of the T cells in early LCL lesions bear the
TCR gd complex (Modlin et al, 1989; Lima et al, 1994).
PATHOGENESIS AND ETIOLOGY
The arthropod vector of all forms of leishmaniasis is the female sand
¯y (Swaminath et al, 1942). The disease is transmitted by ¯ies of the
genus Phlebotomus in the Old World and in the New World it is
transmitted primarily by Lutzomyia and rarely by Psychodopygus.
The transmission cycle of the leishmania organisms requires an
arthropod vector and a mammalian reservoir. The parasite assumes
two distinct forms during the life cycle: an extracellular, ¯agellated
promastigote form, and a non¯agellated obligate intracellular form
called the amastigote. During the course of probing the skin, the
sand ¯y injects saliva containing the promastigote form of
leishmania. The promastigote is taken up by macrophages and
transformed into the round amastigote form. The parasite then
resides in the phagolysosome of the macrophage and proliferates
despite the presence of lysosomal enzymes. When a sand ¯y bites an
infected host, amastigotes taken up during the blood meal transform
back to the promastigote form in the gut of the ¯y, completing the
life cycle. In hyperendemic regions, such as Israel, Jordan, and
Saudi Arabia, L. major promastigotes are occasionally recoverable
from 20% to 50% of female sand ¯ies, but in other areas less than 1%
of sand ¯ies are infected (Norton et al, 1992). Humans are usually
accidental hosts of leishmaniasis, because they live in endemic zones
and are thereby exposed to infected sand ¯ies. The zoonotic
reservoir includes sloths, anteaters, rodents, foxes, and dogs.
Transmission of leishmania infection occurs almost exclusively via
the bite of an infected sand ¯y; however, other possible modes of
transmission (e.g., direct contact) have been reported (Nanji and
Greenway, 1985; Yadav et al, 1989; Eltoum et al, 1992).
IMMUNOLOGY
Leishmaniasis is characterized by a spectrum of disease phenotypes
that corresponds to the strength of the host's cell-mediated immune
response. Both susceptible and resistant phenotypes exist within
human populations. For example, many people in endemic regions
develop positive skin tests without ever manifesting signs of clinical
disease. Spontaneously healing lesions are associated with positive
antigen-speci®c T cell responsiveness, diffuse cutaneous and
visceral disease with T cell nonresponsiveness, and mucocutaneous
disease with T cell hyperresponsiveness. (Blackwell, 1992) Current
research is focused on determining the extent to which this
spectrum of host response to leishmaniasis is genetically deter-
mined. An extensive literature exists on the immunology of
leishmaniasis. The reader is referred to this literature with respect to
cytokines, T cells of the Th1 and Th2 subtypes, killer T cells,
humoral responses, and nitric oxide. (Pirmez et al, 1993; BardaroÂ
and Johnson, 1993; Kemp et al, 1993; Assreuy et al, 1994; Stenger et
al, 1994; Davidson, 1998; Lezama-Davila et al, 1998; Maasho et al,
1998; Etges and Muller, 1998; Jones et al, 1998; Herwaldt, 1999;
Mossalayi et al, 1999).
DIAGNOSIS
In endemic areas, the diagnosis is often made on clinical grounds
alone, based on the following observations: (a) small number of
lesions (1±3); (b) lesions situated on exposed areas; (c) lesions
present for a number of months; (d) lesions resistant to all types of
attempted treatments, and (e) usually no pain or itching. Multiple
diagnostic techniques are available. Historically, microscopy and
culture have been the standard for diagnosis. A punch or wedge
biopsy may be performed, preferably from the indurated border of a
lesion and not from a necrotic center. A touch prep or Giemsa-
stained tissue impression slide may be done on excised tissue, scalpel
scrapings, slit skin smears, or dermal cells obtained using a root
canal ®le. Fine needle aspiration of a lesion may be done after
injection of sterile saline. In cases of suspected VL, splenic aspirates
are used. Specimens from a biopsy or aspirate may be cultured on
NNN blood agar (Nicolle's modi®cation of Novy and McNeal's
medium) or rabbit blood agar, with the growth of promastigotes
apparent between 2 d and 2 wk.
The identi®cation of the speci®c species of parasite responsible
for infection is important for the diagnosis of disease, evaluation of
therapy, and prognosis. Consequently, a number of molecular
biology techniques have been developed that are designed for
species-speci®c identi®cation of parasites within the genus
Leishmania. Monoclonal antibodies (McMahon-Pratt et al, 1982)
and isoenzyme analysis (Kilgour et al, 1974) have been used.
Oligonucleotide primers based on kDaNA sequences have been
used in the polymerase chain reaction (PCR) (de Bruijn and
Barker, 1992; Katakura et al, 1998; El Tai et al, 2001). Species
identi®cation has been achieved in a variety of ways, such as
multiplexing and using nested PCR (Aransay et al, 2000). The
widespread clinical usefulness of these techniques remains to be
implemented.
LEISHMANIA AND HIV CO-INFECTION
Over the past decade, leishmaniasis has been increasingly docu-
mented in immunocompromised patients, namely those infected
with HIV (Machado, 1992; Gillis et al, 1995; Coutinho et al, 1996;
Kubar et al, 1998; Mattos et al, 1998; Castellano et al, 1999; Lachaud
et al 2000; Santos-Gomes et al, 2000). Although leishmaniasis has
been reported in other immunodepressed states, such as diabetes
(Fig 3), PKDL in renal transplant recipients, or in those taking
corticosteroids, the greater magnitude of the former problem
compels us to focus our discussion on concomitant Leishmania and
HIV infections (Alrajhi et al, 1998; Roustan et al, 1998). Co-
infection is most frequently manifested as VL (WHO, 2000).
Epidemiology The increased appearance of leishmaniasis in
developed countries can be attributed to several factors: increased
overseas travel, U.S. Gulf War veterans, and the simultaneous
encroachment of leishmaniasis into urban areas and of HIV
infection into rural areas (Lopez-Velez et al, 1998; Herwaldt,
1999). In the Mediterranean, where L. infantum is endemic, the
number of cases of VL in HIV-infected patients has increased
dramatically since the mid-1980s (Santos-Gomes et al, 2000). The
World Health Organization (WHO) estimates that 25%±70% of
adult VL cases in southern Europe are related to HIV, while
between 2% and 9% of AIDS patients are at risk of experiencing
newly acquired or reactivated VL (Sulahian et al, 1997; Kubar et al,
1998; Rosenthal et al, 2000). Surveillance data for southern Europe
recorded 1461 cases of co-infection from January 1990 through
June 1998, with the majority (57.2%) reported in Spain (Herwaldt,
1999). In some regions of Spain and Portugal, VL is the third most
common opportunistic infection in HIV-infected patients after
Toxoplasma gondii and Cryptosporidium parvum (Alvar et al, 1997). In
fact, preliminary data suggest that Leishmania may be a cofactor in
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the pathogenesis of HIV infection: the lipophosphoglycan (LPG)
surface molecule of L. donovani has been shown to induce
transcription of HIV in CD4+± T cells (Pineda et al, 1998;
Herwaldt, 1999). The WHO estimates that AIDS increases the risk
of VL by 100±1000 times in endemic regions (WHO, 2000).
Despite the strong connection between leishmaniasis and HIV,
Leishmania infection is still not included on the list of AIDS-
de®ning criteria (Alvar et al, 1997; Rosenthal et al 2000).
The typical clinico-epidemiologic pro®le of a co-infected
individual is a young male intravenous drug user (IVDU) infected
with L. infantum, with a CD4+ T cell count below 200 per ul.´ It is
clear that IVDU are the population most at risk for co-infection in
south-western Europe (WHO, 2000). Some researchers have
proposed an anthropoonotic mode of transmission via the sharing
of contaminated needles by IVDU to explain the high frequency of
HIV and Leishmania co-infection in this risk group (Alvar et al,
1997; Hall, 1997; Agostoni et al, 1998; Lopez-Velez et al, 1998).
Although there is no direct evidence of the spread of L. infantum
through this vehicle, the generation of such a hypothesis demon-
strates the heightened awareness of the medical community for the
role of leishmaniasis in HIV-positive patients (Hall, 1997). Two
troubling reports noted parasitemia in asymptomatic blood donors,
detected by PCR and/or culture, from an endemic region (le
Fichoux et al, 1999; Otero et al, 2000). Blood transfused from such
donors into HIV-positive individuals could contribute to the
incidence of co-infection.
Immunology of leishmaniasis in HIV The host's immune
system plays an important role in disease resistance and
susceptibility. The T cell-mediated response directed at infected
macrophages is of prime signi®cance in leishmanial destruction
(Castellano et al, 1999). It follows that the depressed CD4+- T cell
levels of HIV-infected patients render them particularly vulnerable
to leishmaniasis. Furthermore, because their de®cient cell-mediated
immunity allows the parasites to disseminate, it is not surprising that
the most commonly reported clinical form of infection is VL. One
study involving 236 HIV-positive patients living in an L. infantum
endemic region used serologic analysis and western blotting to
follow the evolution of CD4+± T cell counts and to study the
relationship between L. infantum infection and VL disease. Overall,
the ratio of VL disease to Leishmania infection in HIV-positive
patients was high (1:10) and comparable with the statistics reported
by the WHO. Nevertheless, 18 of the 32 HIV-positive, L. infantum-
seropositive patients did not develop VL, despite severe and
prolonged immunosuppression (CD4+± T cell counts lower than
250 cells 3 106 per liter) in eight of these individuals. An
unexpected ®nding was that VL patients with very low CD4+±
T cell counts could maintain speci®c anti-leishmanial antibody
production. Finally, because clinical manifestations appeared at
signi®cantly higher (p = 0.028) CD4+± T cell levels at the time of
diagnosis for primary VL patients than for reactivation of a latent
Leishmania infection, the researchers suggested that supplementary
control mechanisms besides the T cell-mediated response may
operate once Leishmania infection and parasite±host interaction
have been well established (Kubar et al, 1998).
Several studies have proposed that HIV-infected patients are
particularly susceptible to certain variants of L. infantum. Rapid
identi®cation of causative Leishmania species using PCR techniques
in 33 patients revealed that L. infantum strains from the
immunocompromised patients with VL had three different DNA
sequences, whereas all strains from the immunocompetent patients
shared an identical sequence (Minodier et al, 1997). Isoenzyming
typing of L. infantum in both immunocompetent and immuno-
compromised patients revealed both a higher variability of
zymodemes and the exclusive presence of speci®c zymodemes in
the immunocompromised patients, which suggests that these
hypovirulent strains are normally contained by the intact cellular
immune systems of immunocompetent hosts (Jimenez et al, 1995;
Agostoni et al, 1998).
Despite the development of more sensitive techniques for
serologic diagnosis, the relatively common lack of a humoral
immune response often leads to delayed diagnosis of VL in the
setting of HIV infection. In those co-infected individuals capable of
mounting a humoral response, it is estimated that speci®c anti-
leishmanial antibody levels are 50 times lower than in individuals
with intact immune systems. Seropositivity may depend on which
infection the patient acquired ®rst. It has been proposed that anti-
leishmanial titers may be higher when Leishmania infection precedes
HIV infection, in which case clinical VL would be a reactivation of
latent infection, while seronegativity results from primary VL
acquired after HIV infection. The overall dysfunction of the
immune system in patients with HIV, however, especially in the
advanced stages of AIDS, may also explain the decrease in speci®c
antibody production (Alvar et al, 1997; Kubar et al, 1998). It is
therefore recommended that two or more serologic tests and
antigens freshly prepared in the laboratory be used to increase
sensitivity (WHO, 2000). Investigators have used PCR as a reliable
tool to diagnose VL in HIV- positive patients and have also
demonstrated that a positive PCR result is predictive of clinical
relapse (Pizzuto et al, 2001).
Clinical manifestations of VL in HIV-infected
individuals Patients who are co-infected with leishmaniasis
and HIV manifest clinical signs and symptoms that are often unique
and can be either more or less severe than usual. These include
greater rates of recurrence, an atypical course of infection, and
localization of Leishmania amastigotes in unusual sites (Sulahian et al,
1997; Lopez-Velez et al, 1998). The severity of VL in HIV-infected
individuals spans a broad spectrum from completely asymptomatic
cases to those manifesting classic VL symptoms. In a retrospective
study conducted in France on 91 co-infected patients, the classic
VL symptoms of fever (87% of patients), splenomegaly (74%), and
hepatomegaly (49%) were common. In 31 (34%) of these cases
amastigotes were discovered in unusual locations such as the
digestive tract (16 patients), lungs (seven), skin (seven), and tonsil
(one). These sites of parasitation, which would be considered
atypical in immunocompetent patients, were only detected in the
most severely immunocompromised patients, with a mean CD4+
T cell count of 20 per ml (Rosenthal et al, 2000). In conjunction
with the unique presentations of VL and HIV co-infection, clinical
diagnosis can be delayed or complicated by the similar features that
characterize HIV infection alone, HIV co-infection with other
opportunistic microorganisms (i.e., mycobacteria), opportunistic
infections concurrent with leishmaniasis, or drug therapy-induced
Figure 3. Generalized cutaneous leishmaniasis believed to be
caused by L. braziliensis in a patient immunocompromised by
diabetes. The term ``generalized'' is used to distinguish this case from
``diffuse'' caused by L. amazonensis.
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side-effects (Agostoni et al, 1998). Furthermore, as mentioned
above, serologic tests are often falsely negative.
Mortality during the ®rst VL episode in HIV-infected patients is
between 10% and 19%, depending on the toxicity of antiparasitic
treatment, concomitant opportunistic infections, and other com-
plications (Alvar et al, 1997). The median survival of HIV-infected
patients with VL is 13±19 mo (Davidson, 1998). In the study of 54
Spanish co-infected patients, 18.5% died during their ®rst episode
of VL. A signi®cant predictor of mortality was the ful®lment of
AIDS-de®ning criteria at the time of VL diagnosis: the relative
mortality risk was 2.42 times higher in patients with an AIDS
diagnosis than in patients who did not meet AIDS-de®ning criteria.
The group of patients with AIDS (n = 26) experienced a dramatic
decrease in percent survival to less than 60% within the ®rst 5 mo
after VL diagnosis, whereas the group of patients without AIDS
(n = 28) reached similar survival levels at approximately 30 mo
after VL diagnosis. The survival curve of this latter group showed
no signi®cant differences compared with the survival curve of the
control group of patients who had AIDS but not VL (Lopez-Velez
et al, 1998).
In contrast to the reliable cure of VL in immunocompetent hosts
who have relapse rates < 5%, more than 80% of VL and HIV co-
infected patients are expected to experience a relapse following
effective treatment of their ®rst episode, with almost all relapses
occuring within 12 mo (Davidson, 1998). The parasite can remain
quiescent in several organs and can be reactivated when the host's
immune system becomes depressed, a predictable event during the
progression from asymptomatic HIV infection to AIDS (Alvar et al,
1997; Lopez-Velez et al, 1998). In addition, the parasite may
develop drug resistance, resulting in incomplete treatment of the
initial VL episode or unresponsiveness to a previously effective drug
during a subsequent relapse of VL. Secondary prophylaxis has been
recommended to minimize these relapses and will be discussed in
Therapy.
Other clinical forms of Leishmania and HIV co-
infection Although the majority of AIDS-related cases
involve L. infantum- induced VL, the total clinical spectrum of
leishmaniasis has been reported in HIV-infected patients.
Cutaneous lesions may occur before, after, or at the same time as
visceral lesions; however, exclusive cutaneous involvement is rare
(Alvar et al, 1997). In one report, a child in the advanced stages of
AIDS presented with an unusual clinical picture of DCL caused by
L. major (Gillis et al, 1995). Unlike the localized papular or nodular
lesions typical of L. major-induced LCL, the child's lesions were
diffusely disseminated, scaly plaques resembling the characteristic
appearance of xeroderma pigmentosum or chronic graft versus host
disease. Antimonial therapy rendered clinical improvement in a
case of generalized cutaneous leishmaniasis in a patient with AIDS
(Rosatelli et al, 1998). Although the association between MCL and
HIV infection is rare, one study documented the presence of
multiple cutaneous lesions with mucosal involvement in young
HIV-infected males with American cutaneous leishmaniasis (Mattos
et al, 1998). The discovery of a dermato®broma colonized by
Leishmania parasites in an HIV-positive man with VL has
prompted the speculation of a new variety of dermal Kala-Azar,
the ®brohistiocytic type (Castellano et al, 1999). This ®nding,
however, could have also represented a secondary leishmanial
parasitation of a previously existing dermato®broma, or even the
casual coexistence of both entities. Leishmanial parasitation of
cutaneous Kaposi's sarcoma in HIV has also been described. In a
study of 22 cases of Mediterranean leishmaniasis and HIV co-
infection, the parasite was recovered from the skin lesions of
Kaposi's sarcoma in two patients who had ®rst been diagnosed
through bone marrow aspiration (Agostoni et al, 1998).
THERAPY
The natural history of leishmaniasis must be considered when
evaluating therapeutic agents. Lesions of cutaneous leishmaniasis
heal spontaneously over 1 mo to 3 y, whereas lesions of
mucocutaneous and visceral disease rarely, if ever, heal without
treatment. Consequently, all cases of MCL and VL require
treatment. Therapy is not always essential in LCL. Patients with
lesions on the face or other cosmetically important area should be
treated to reduce the size of the resultant scar. In addition, the
species of parasite should be identi®ed so that infection with L.
braziliensis and L. panamensis can be treated to reduce the risk of
development of mucocutaneous disease. Treating patients with
Leishmania and HIV co-infection requires close monitoring for
effectiveness of treatment, especially due to high relapse rates.
The pentavalent ammonial compound sodium stibogluconate
(Pentostam) remains the conventional therapeutic agent after 50 y
(http://www.medletter.com; WHO, 2000). The drug appears to
inhibit amastigote glycolytic activity and fatty acid oxidation. It is
available from the Centers for Disease Control to treat cases
diagnosed in the U.S.A. by calling (770) 488±7760. The CDC will
also aid in making a diagnosis. The accepted concentration for the
treatment of leishmaniasis is 20 mg per kg IV or IM daily, with an
upper limit of 30 mg per kg per daily dose (Berman, 1988).
Cutaneous leishmaniasis is treated for 20 d and visceral and mucosal
disease for 28 d. Side-effects associated with parenteral antimonial
administration include arthralgias, myalgias, abdominal discomfort,
reversible elevations of hepatocellular enzymes, chemical pancrea-
titis, and occasional anemia, leukopenia, or thrombocytopenia.
Changes in the EKG commonly develop, and occur more
frequently the higher the daily dose and the longer the duration
of therapy. The EKG abnormalities include T wave inversion, ST
segment elevation or depression, and prolongation of the QT
interval. A review on the use of Pentostam for the treatment of
leishmaniasis generated several recommendations with regard to
these side-effects (Herwaldt and Berman, 1992).
In the U.S.A., most patients are admitted for cardiac monitoring
during treatment with Pentostam. In South America, where a
slightly different pentavalent antimonial, meglumine antimoniate
(Glucantime), is available, the drug is often administered at home.
Glucantime is administered at 85% of the dose of Pentostam, and
both drugs have similar ef®cacy. The antimonials have a reported
ef®cacy of > 90% in most studies, although cure rates ranging from
34% to 100% have been reported, depending on the parasite species
and the dose and duration of treatment.
A wide variety of alternative systemic and topical treatments have
been utilized to treat leishmaniasis (Table I). Most of these
treatments have not been analyzed with randomized, placebo-
controlled trials, making it dif®cult to accurately evaluate their
Table I. Therapeutic options for leishmaniasisa
Therapeutic agent LCL DCL MCL VL Reference
Antimonials (IV/IM) E E E E 1,72
Antimonials (IL) E 71
Pentamidine E E 1,73
Amphotericin B E E E 1,74
Interferon w/antimony ? E E 34
Allopurinol ? ? 75
Ketoconazole E 77
Itraconazole ? ? ? 76
Immunotherapy ? 78
Rifampin ? 71
Dapsone ? 71
Localized heat ? ? 81
Paromomycin ointment E 80
Cryotherapy ? 79
WR6026 I 82
Liposomes E E 55,56
Miltefosine ? 84
aLCL, localized cutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis;
MCL, mucocutaneous leishmaniasis; VL, visceral leishmaniasis; E, believeable
effectiveness; ?, current clinical experience too limited; I, investigational.
VOL. 6, NO. 3 DECEMBER 2001 LEISHMANIASIS 179
effectiveness. A few conclusions, however, may be drawn:
Pentamidine has been used successfully as a second-line agents for
VL and New World CL (Soto-Mancipe et al, 1993). Amphotericin
B has some effectiveness in mucosal disease (Sampaio et al, 1971).
The combination of antimony and interferon-g has been used
effectively in the treatment of refractory VL in Brazil but the
improvement in cure rates has been deemed only modest
(Davidson, 1998). Granulocyte macrophage colony-stimulating
factor in combination with antimonials for the treatment of VL can
induce a quicker rise in leukocytes and fewer secondary infections
(Davidson, 1998). The combination of immunotherapy with
chemotherapy for leishmaniasis remains experimental, and the
cost of such regimens precludes their routine use. Some clinicians
favor the use of cryotherapy, especially combined with EMLA
anesthesia, as a practical means of treating LCL in young patients.
Current clinical experience with other agents is too limited to
draw any ®rm conclusions. A placebo-controlled clinical trial
showed some effectiveness of ketoconazole in treatment of LCL in
South America (Navin et al, 1992). Interestingly, ketoconazole may
be more effective than antimony in treating L. mexicana infections,
but less effective in L. braziliensis infections. Itraconazole has shown
some promise in uncontrolled trials, most recently in a pilot study
for the treatment of ML (Amato et al, 2000). Trials with allopurinol
have shown mixed results (Velez et al, 1997). Finally, immu-
notherapy consisting of three vaccinations of live Bacille Calmette
Guerin (BCG) with killed leishmania promastigotes was compar-
able in ef®cacy with three standard courses of antimony in
Venezuelan LCL (Convit et al, 1987). With regard to topical
therapy, paromomycin ointment, localized heat, and cryotherapy
have all been tried with variable results (Bassiouny et al, 1982; El-
On et al, 1992; Levine, 1992). Combinations of therapeutic
strategies should be researched in the future.
The administration of drug-containing liposomes in theory
delivers the therapeutic agent of choice directly to macrophages in
which amastigotes reside. Three liposomal formulations of
amphotericin B are available, but only one (``AmBisome'') is
licensed for the treatment of VL in Europe and the U.S.A.
AmBisome therapy is rapidly effective and less toxic than
conventional formulations of amphotericin B (Alrajhi et al, 1998);
however, the liposomal formulation is also more than 50 times
more expensive than the conventional formulation (Roustan et al,
1998). Liposomal amphotericin B should be used for the treatment
of VL when costs of hospitalization would exceed drug costs.
WR 6026 is a primaquine analog that has shown effectiveness in
animal models of VL, and underwent a phase II clinical ef®cacy trial
in the treatment of 16 patients with kala azar. Adverse effects
included gastrointestinal distress, headache, and methemoglobine-
mia (Sherwood et al, 1994). We have not been able to identify any
reports since this one from 1994 on the use of WR 6026 in the
treatment of leishmaniasis.
Currently, there is no effective oral medication for the treatment
of leishmaniasis. In a small clinical trial, oral zinc sulfate was used to
treat cutaneous leishmaniasis and showed concentration-dependent
cure rates of up to 96.9% (Sharquie et al, 2001). Miltefosine, a
phosphocholine analog that interferes with cell-signaling pathways
and membrane synthesis, was recently tested in phase II clinical
trials for the treatment of Indian VL in a large population.
Gastrointestinal side-effects were frequent, but ®nal cure rates
ranged between 93% and 97%. Therefore, miltefosine is the ®rst
oral agent that appears to be both highly effective and well tolerated
for the treatment of VL (Jha et al, 1999).
The treatment of VL in HIV-infected patients is based on the
therapy recommended for treating VL in immunocompetent
patients. AmBisome is currently the only drug licensed for VL in
the U.S.A. The treatment of choice, the best dosage, and the
duration are still unknown for this group of patients. The
management of HIV-infected patients with VL warrants special
attention for several reasons. First, it is estimated that 60%±90% of
AIDS patients experience a relapse of the disease after responding
well to initial treatment, making post-therapeutic follow-up
essential (Lachaud et al, 2000). In other cases, response to treatment
may be incomplete or may be interrupted by drug toxicity.
Although reports of severe pancreatitis, myocarditis, and renal
insuf®ciency due to antimonial therapy in co-infected patients have
been described, it has not been established that drug tolerance in
HIV- infected patients is poorer than in immunocompetent
patients (Alvar et al, 1997). The optimal regime for secondary
prophylaxis and management of harmful drug±drug interactions
while on concomitant antiretroviral therapy are areas to be
investigated further.
VACCINATION
Methods used for prevention or control of leishmaniasis have
included eradication of the vector or its habitat, destruction of
animal reservoirs, treatment of human reservoirs, and vaccination.
Technical dif®culties such as drug resistance, drug toxicity,
insecticide resistance, ®nancial constraints, and operational dif®-
culties have impaired progress toward effective control of
leishmaniasis.
Vaccination trials in animal models and/or humans have been
performed using virulent promastigotes, promastigotes attenuated
or killed with either gamma irradiation, heat, or a mutagen, and
speci®c antigens puri®ed from promastigotes (Higashi, 1988;
Nadim and Javadian, 1998). Reduced rates of subsequent infection
have been noted in vaccinated populations. Side-effects include
large, nonhealing lesions that persist for years and eventually require
treatment, and immediate-type hypersensitivity reactions, which
may last for a few hours.
The use of cytokines as adjuvants to vaccines is being investi-
gated. IL-12 has been shown to be an effective adjuvant in
experimental vaccination against L. major infection. Also, vaccin-
ation with the DNA that encodes the LACK antigen of L. major
can induce an IL-12- mediated, protective Th1 response (Herwaldt
et al, 1993).
The development of an effective, noninfectious vaccine is
problematic. The dif®culty associated with the development of a
vaccine directed against the parasite suggests that evaluation of a
vaccine based on the vector should be attempted. As vaccines for
leishmaniasis are being taken to clinical trials, long-term follow-up
will be necessary to determine the degree and duration of
protection. Control and prevention of leishmaniasis in the future
depends on the development of more ef®cacious vaccines and
convenient, nontoxic therapeutic agents.
CONCLUSION
Leishmaniasis is a fascinating protozoal disease with varied clinical
and pathologic manifestations. The increasing incidence of travel
and co-infection with Leishmania and HIV during the last two
decades has focused more attention on leishmaniasis. It is hoped
that this attention will lead to better therapeutic agents to treat, and
vaccines to prevent, this emerging infection.
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